Structure-Based Analysis of Boronic Acids As Inhibitors of Acinetobacter-Derived Cephalosporinase-7, a Unique Class C β-Lactamase
Overview
Microbiology
Pharmacology
Authors
Affiliations
Acinetobacter baumannii is a multidrug resistant pathogen that infects more than 12 000 patients each year in the US. Much of the resistance to β-lactam antibiotics in Acinetobacter spp. is mediated by class C β-lactamases known as Acinetobacter-derived cephalosporinases (ADCs). ADCs are unaffected by clinically used β-lactam-based β-lactamase inhibitors. In this study, five boronic acid transition state analog inhibitors (BATSIs) were evaluated for inhibition of the class C cephalosporinase ADC-7. Our goal was to explore the properties of BATSIs designed to probe the R1 binding site. K values ranged from low micromolar to subnanomolar, and circular dichroism (CD) demonstrated that each inhibitor stabilizes the β-lactamase-inhibitor complexes. Additionally, X-ray crystal structures of ADC-7 in complex with five inhibitors were determined (resolutions from 1.80 to 2.09 Å). In the ADC-7/CR192 complex, the BATSI with the lowest K (0.45 nM) and greatest Δ T (+9 °C), a trifluoromethyl substituent, interacts with Arg340. Arg340 is unique to ADCs and may play an important role in the inhibition of ADC-7. The ADC-7/BATSI complexes determined in this study shed light into the unique recognition sites in ADC enzymes and also offer insight into further structure-based optimization of these inhibitors.
Activity of Organoboron Compounds against Biofilm-Forming Pathogens.
Konaklieva M, Plotkin B Antibiotics (Basel). 2024; 13(10).
PMID: 39452196 PMC: 11504661. DOI: 10.3390/antibiotics13100929.
Powers R, June C, Fernando M, Fish E, Maurer O, Baumann R J Med Chem. 2023; 66(13):8510-8525.
PMID: 37358467 PMC: 10350917. DOI: 10.1021/acs.jmedchem.3c00144.
Introvigne M, Beardsley T, Fernando M, Leonard D, Wallar B, Rudin S Antibiotics (Basel). 2023; 12(4).
PMID: 37107006 PMC: 10135033. DOI: 10.3390/antibiotics12040644.
Drug‑resistant : From molecular mechanisms to potential therapeutics (Review).
Wu H, Xiao Z, Lv X, Huang H, Liao C, Hui C Exp Ther Med. 2023; 25(5):209.
PMID: 37090073 PMC: 10119666. DOI: 10.3892/etm.2023.11908.
Class C β-Lactamases: Molecular Characteristics.
Philippon A, Arlet G, Labia R, Iorga B Clin Microbiol Rev. 2022; 35(3):e0015021.
PMID: 35435729 PMC: 9491196. DOI: 10.1128/cmr.00150-21.